Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer

Medchemcomm. 2017 Aug 25;8(10):1914-1918. doi: 10.1039/c7md00305f. eCollection 2017 Oct 1.

Abstract

ALK-fusion proteins play a fundamental role in the development of about 5% of non-small cell lung cancers. Herein, we identified the compound 5067-0952 as a potent ALK inhibitor, which inhibited cell growth, induced apoptosis, and suppressed the phosphorylation of ALK, subsequently blocking its downstream signaling pathway.